EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC

EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC

Abstract Background The bromodomain and extra-terminal domain (BET) inhibitor is a type of anti-tumor agent, currently being evaluated in phase I and II clinical trials for cancer therapy. It can decrease MYC expression levels and cause effective anti-tumor effects in diverse human cancers. However,...

Full description

Bibliographic Details
Main Authors: Yalei Yin, Mingju Sun, Xi Zhan, Changqing Wu, Pengyu Geng, Xiaoyan Sun, Yunsong Wu, Shuijun Zhang, Jianhua Qin, Zhengping Zhuang, Yang Liu
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Bromodomain
JQ1
MAPK pathway
MYC
EGFR mutation
Sorafenib
Online Access:http://link.springer.com/article/10.1186/s13046-019-1082-6

Internet

http://link.springer.com/article/10.1186/s13046-019-1082-6

Similar Items